Study of myMS in Participants With a Diagnosis of Multiple Sclerosis
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03111394 |
Recruitment Status :
Active, not recruiting
First Posted : April 12, 2017
Last Update Posted : April 1, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Multiple Sclerosis |
This is a pilot study evaluating the feasibility of a mobile application "myMS™" to collect active clinical tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), magnetic resonance imaging information and conduct genome-wide association studies in subjects with multiple sclerosis. Participants will be self-referred to this study from different sources; patient advocacy groups, social media tools, clinicaltrials.gov, and flyers.
Specific aims of this pilot study are:
- To determine the feasibility and work flow in prospectively collecting surveys, clinical tasks, magnetic resonance imaging (MRI) information for up to 200 self-referred adult MS participants, using mobile app myMS™.
- To determine the feasibility of using interface between myMS™ and 23andMe® DNA Kits and 23andme password protected mobile app platform (GSR Dashboard) in collecting one biological (saliva) sample and distributing the genetic result (using commercially available results only, distributed by 23andme®), for up to 200 self-referred adult MS participants. This aim is for testing the system interface only. 23andme® has their own independent consent form and IRB coverage for their commercial product.
- To estimate the percentage of registered participants that will meet eligibility criteria for MS.
- To estimate the percentage of participants that a) complete all clinical tasks; b) complete all surveys; c) provide genetic information; and d) provide MRI scans.
Study Type : | Observational |
Estimated Enrollment : | 200 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis |
Actual Study Start Date : | April 17, 2017 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2020 |

- Participants willing to provide genetic and MRI data via myMS [ Time Frame: 12 months ]Proportion of participants with both genetic and MRI data available
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Males or females participants with access to an iPhone 5 and above.
- Participants willing to provide electronic consent.
- Age 18 and above.
- A diagnosis of MS (Polman, 2010), with dissemination in time and space. CIS participants will be included if they fulfil 3 of the 4 MRI criteria for dissemination in space as per Polman et al. 2010.
- EDSS of between 0 and 8.0
Exclusion Criteria:
- Under 18 years of age
- Participants who do not consent to participate.
- Participants participating in ongoing MS clinical trials with non-approved drugs.
- Any concurrent illness, disability or clinically significant abnormality (including laboratory tests) that may prevent the subject from safely completing the assessments required by the protocol.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03111394
United States, California | |
Aimslab@Usc.Edu | |
Los Angeles, California, United States, 90033 |
Principal Investigator: | Daniel Pelletier, M.D. | Keck School of Medicine of USC, University of Southern California |
Responsible Party: | Daniel Pelletier, Professor of Neurology; Vice Chair, Clinical Research, Department of Neurology; Division Chief, Neuro-Immunology and USC Multiple Sclerosis Center, University of Southern California |
ClinicalTrials.gov Identifier: | NCT03111394 History of Changes |
Other Study ID Numbers: |
HS-16-00579 |
First Posted: | April 12, 2017 Key Record Dates |
Last Update Posted: | April 1, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | Participants will have the option to opt in or out for researchers to be able to share individual participant data (IPD) with researchers outside of USC. |
MS 23andMe MRI Genome-wide association studies |
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System |
Nervous System Diseases Demyelinating Diseases Autoimmune Diseases Immune System Diseases |